HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Goes On Offensive Against Prescription Pseudoephedrine Trend

This article was originally published in The Tan Sheet

Executive Summary

Drug firms hope to dissuade states from moving drugs that contain methamphetamine precursors to prescription status by funding electronic systems to track nonprescription sales of the products

You may also be interested in...



Tennessee Emerges As PSE Battleground With Rx, NPLEx Proposals

The conflict between electronic tracking of pseudoephedrine purchases and shifting the drug ingredient to prescription-only status is elevated in Tennessee as lawmakers offer bills for both anti-methamphetamine strategies.

Industry Must Adapt To Emerging Trends That Threaten Recent Economic Gain

The OTC industry must adapt to evolving market trends as the global economy recovers in order to maintain the market share it gained during the recession, said experts at a European industry conference

Senate Meth Fight Pits Rx-Only Pseudoephedrine Against E-Tracking Option

The debate over how best to keep methamphetamine precursors from diversion to illicit drug labs is coming to a head as lawmakers stake out positions and legislation to restrict nonprescription access to pseudoephedrine waits in the wings

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS136308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel